Weight ManagementAlso known as: LY3502970, ATTAIN trial, oral non-peptide GLP-1
Orforglipron
First oral non-peptide GLP-1 receptor agonist from Eli Lilly — in Phase 3 ATTAIN trials. Unlike oral semaglutide (which is still a peptide), orforglipron is a small molecule with no absorption enhancer needed.
Half-Life
~25-50 hours
Dose Range
12-36-45 mg/day (oral)
Frequency
1× daily (oral)
Vial Sizes
N/A (oral)
Mechanism of Action
Non-peptide small-molecule full agonist of GLP-1R that does not require absorption enhancers (SNAC). Orally bioavailable, resistant to gut proteases, and activatable at standard stomach pH. Achieves ~14.7% body weight loss at 36 mg in Phase 2.
Source: PMID: 37351564 (Phase 2 NEJM)
Dosing Protocol
| Typical Dose | 12-36-45 mg/day (oral) |
| Frequency | 1× daily (oral) |
| Half-Life | ~25-50 hours |
Dosing Quick Reference
Orforglipron— Dosing Guide
Dose Range
12-36-45 mg/day (oral)
Half-Life
~25-50 hours
Frequency
1× daily (oral)
Route
Oral
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code